Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Fulgent Genetics, Inc. operates as a technology company. The Company develops a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools, and integrated laboratory processes. Fulgent Genetics offers genetic testing to provide physicians with clinically diagnostic information.
Website: fulgentgenetics.com



Growth: Bad revenue growth rate -3.0%, there is slowdown compared to average historical growth rates 0.8%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of -81.0%

Profitability: LTM EBITDA margin is negative, -59.7%. On average the margin is improving steadily. Gross margin is normal, +31.2%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.37 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -3.8% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 10.4% higher than minimum and 80.1% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -1.4x by EV / Sales multiple

Key Financials (Download financials)

Ticker: FLGT
Share price, USD:  (-1.7%)22.11
year average price 28.86  


year start price 37.76 2023-05-19

max close price 40.81 2023-07-19

min close price 20.03 2024-04-25

current price 22.11 2024-05-18
Common stocks: 29 769 000

Dividend Yield:  0.0%
Last revenue growth (y/y):  -3.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  0.8%
Historical growth of EBITDA:  -27.8%
EV / Sales: -0.7x
Margin (EBITDA LTM / Revenue): -59.7%
Fundamental value created in LTM:
Market Cap ($m): 658
Net Debt ($m): -846
EV (Enterprise Value): -188
Price to Book: 0.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-05-03Zacks Investment Research

Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Misses Revenue Estimates

2023-11-03Seeking Alpha

Fulgent Genetics, Inc. (FLGT) Q3 2023 Earnings Call Transcript

2023-08-04Zacks Investment Research

Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Tops Revenue Estimates

2023-07-29Seeking Alpha

Fulgent Genetics: Post-Pandemic Devaluing Appears Overdone

2023-05-23The Motley Fool

2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years

2023-05-14Seeking Alpha

What To Expect From Fulgent Genetics In 2023

2023-05-08Zacks Investment Research

Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?

2023-05-05Zacks Investment Research

Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Tops Revenue Estimates

2023-04-12Zacks Investment Research

Are Medical Stocks Lagging Fulgent Genetics (FLGT) This Year?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol FLGT FLGT FLGT FLGT FLGT FLGT FLGT
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-03 2024-02-28 2023-11-03 2023-08-04 2023-05-05 2023-02-28 2022-11-07
acceptedDate 2024-05-03 07:34:20 2024-02-28 17:03:25 2023-11-03 07:31:48 2023-08-04 07:14:47 2023-05-05 07:24:47 2023-02-28 16:49:57 2022-11-07 16:36:02
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 64M 71M 85M 68M 66M 68M 106M
costOfRevenue 44M 47M 45M 47M 47M 55M 60M
grossProfit 20M 23M 40M 21M 19M 13M 46M
grossProfitRatio 0.312 0.330 0.470 0.303 0.284 0.192 0.436
researchAndDevelopmentExpenses 11M 12M 10M 10M 10M 9M 8M
generalAndAdministrativeExpenses 21M 32M 17M 18M 22M 29M 26M
sellingAndMarketingExpenses 9M 11M 10M 11M 10M 10M 10M
sellingGeneralAndAdministrativeExpenses 30M 42M 28M 29M 32M 39M 36M
otherExpenses 0 -6M 2M 2M 2M 2M 2M
operatingExpenses 42M 54M 40M 40M 44M 50M 46M
costAndExpenses 86M 101M 84M 88M 91M 104M 105M
interestIncome 8M 6M 7M 5M 4M 3M 1M
interestExpense 0 36M 54 000 206 000 -4M 3M 1M
depreciationAndAmortization 7M 7M 6M 6M 2M 2M 2M
ebitda -15M -24M 7M -13M -23M -35M 3M
ebitdaratio -0.235 -0.345 0.078 -0.199 -0.345 -0.511 0.024
operatingIncome -22M -31M 214 000 -20M -25M -37M 562 000
operatingIncomeRatio -0.338 -0.438 0.003 -0.292 -0.375 -0.540 0.005
totalOtherIncomeExpensesNet 8M -114M 7M 5M 4M 3M 1M
incomeBeforeTax -14M -145M 7M -15M -21M -33M 2M
incomeBeforeTaxRatio -0.220 -2.059 0.081 -0.217 -0.318 -0.494 0.017
incomeTaxExpense -327 000 -11M 20M -3M -5M -9M 414 000
netIncome -13M -128M -13M -11M -16M -24M 1M
netIncomeRatio -0.209 -1.818 -0.155 -0.165 -0.240 -0.356 0.013
eps -0.450 -4.300 -0.440 -0.380 -0.540 -0.810 0.045
epsdiluted -0.450 -4.300 -0.440 -0.380 -0.540 -0.810 0.044
weightedAverageShsOut 30M 30M 30M 30M 30M 30M 30M
weightedAverageShsOutDil 30M 30M 30M 30M 30M 30M 31M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol FLGT FLGT FLGT FLGT FLGT FLGT FLGT
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-03 2024-02-28 2023-11-03 2023-08-04 2023-05-05 2023-02-28 2022-11-07
acceptedDate 2024-05-03 07:34:20 2024-02-28 17:03:25 2023-11-03 07:31:48 2023-08-04 07:14:47 2023-05-05 07:24:47 2023-02-28 16:49:57 2022-11-07 16:36:02
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 55M 97M 84M 58M 66M 80M 169M
shortTermInvestments 251M 327M 384M 400M 805M 773M 749M
cashAndShortTermInvestments 306M 424M 468M 458M 871M 853M 918M
netReceivables 59M 57M 55M 40M 44M 53M 104M
inventory 7M 6M 5M 6M 5M 4M 8M
otherCurrentAssets 21M 26M 33M 35M 33M 22M 10M
totalCurrentAssets 387M 508M 550M 528M 915M 906M 1 022M
propertyPlantEquipmentNet 96M 94M 85M 88M 79M 81M 82M
goodwill 22M 22M 142M 142M 143M 143M 120M
intangibleAssets 141M 143M 144M 146M 149M 151M 88M
goodwillAndIntangibleAssets 163M 165M 286M 288M 292M 294M 208M
longTermInvestments 561M 444M 399M 401M 380M 339M 358M
taxAssets 0 30M 0 0 0 0 0
otherNonCurrentAssets 23M 32M 38M 49M -289M -234M -265M
totalNonCurrentAssets 843M 765M 809M 826M 462M 480M 384M
otherAssets 0 1.000 0 0 0 0 0
totalAssets 1 230M 1 273M 1 358M 1 355M 1 377M 1 386M 1 406M
accountPayables 20M 15M 16M 21M 22M 23M 14M
shortTermDebt 4M 6M 3M 5M 21M 21M 20M
taxPayables 0 0 0 0 0 0 426 000
deferredRevenue 3M 3M 21M 17M 14M 14M 28M
otherCurrentLiabilities 50M 49M 21M 23M 51M 58M 61M
totalCurrentLiabilities 76M 73M 61M 65M 108M 116M 124M
longTermDebt 2M 10M 3M 0 0 0 0
deferredRevenueNonCurrent 7M -888 000 -3M 0 0 0 0
deferredTaxLiabilitiesNonCurrent 13M 52M 10M 10M 0 0 0
otherNonCurrentLiabilities 5M 6M 25M 17M 26M 28M -42M
totalNonCurrentLiabilities 27M 67M 35M 26M 26M 28M 22M
otherLiabilities 0 0 0 0 -26M -28M -22M
capitalLeaseObligations 7M 9M 10M 11M 0 0 0
totalLiabilities 103M 140M 97M 91M 108M 116M 124M
preferredStock 20M 20M 15M 13M 13M 0 0
commonStock 3000.000 3000.000 3000.000 3000.000 3000.000 3000.000 3000.000
retainedEarnings 620M 633M 761M 774M 786M 801M 825M
accumulatedOtherComprehensiveIncomeLoss -1M 1M -17M -21M -17M -21M -26M
othertotalStockholdersEquity 491M 481M 499M 493M 487M 490M 482M
totalStockholdersEquity 1 130M 1 136M 1 259M 1 260M 1 269M 1 270M 1 281M
totalEquity 1 127M 1 133M 1 262M 1 263M 1 273M 1 270M 1 281M
totalLiabilitiesAndStockholdersEquity 1 230M 1 273M 1 358M 1 355M 1 377M 1 386M 1 406M
minorityInterest -3M -3M 3M 4M 4M 3M 0
totalLiabilitiesAndTotalEquity 1 230M 1 273M 1 358M 1 355M 1 377M 1 386M 1 406M
totalInvestments 812M 771M 767M 788M 805M 786M 760M
totalDebt 13M 15M 3M 5M 21M 21M 20M
netDebt -42M -83M -81M -54M -46M -59M -148M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol FLGT FLGT FLGT FLGT FLGT FLGT FLGT
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-03 2024-02-28 2023-11-03 2023-08-04 2023-05-05 2023-02-28 2022-11-07
acceptedDate 2024-05-03 07:34:20 2024-02-28 17:03:25 2023-11-03 07:31:48 2023-08-04 07:14:47 2023-05-05 07:24:47 2023-02-28 16:49:57 2022-11-07 16:36:02
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -13M -128M -13M -12M -16M -24M 1M
depreciationAndAmortization 7M 7M 6M 6M 7M 10M 10M
deferredIncomeTax -557 000 502 000 19M -3M -5M 5M 3M
stockBasedCompensation 12M 11M 11M 10M 10M 10M 9M
changeInWorkingCapital 5M 10M -11M 9M -5M 23M -11M
accountsReceivables 1M -5M -12M 10M 9M 44M 22M
inventory 0 0 0 0 0 0 0
accountsPayables -245 000 129 000 -3M -3M -2M 7M -22M
otherWorkingCapital 4M 15M 3M 843 000 -7M -28M -12M
otherNonCashItems 22M 114M -2M -668 000 791 000 10M 9M
netCashProvidedByOperatingActivities 7M 15M 10M 10M -8M 33M 21M
investmentsInPropertyPlantAndEquipment -4M -3M -5M -12M -2M 5M -5M
acquisitionsNet 258 000 -64 000 22 000 220 000 0 -45M 0
purchasesOfInvestments -196M -148M -93M -107M -144M -161M -12M
salesMaturitiesOfInvestments 152M 176M 118M 117M 141M 108M 61M
otherInvestingActivites 258 000 28M 25M 0 198 000 172 000 222 000
netCashUsedForInvestingActivites -47M 24M 20M -1M -4M -93M 44M
debtRepayment -900 000 -2M -2M -16M -232 000 -231 000 -238 000
commonStockIssued 0 -3000.000 0 3000.000 0 31 000 0
commonStockRepurchased -225 000 -23M -2M -232 000 0 -29M -35M
dividendsPaid 0 0 0 -229 000 0 0 0
otherFinancingActivites -2M -1M -517 000 229 000 -869 000 -335 000 -522 000
netCashUsedProvidedByFinancingActivities -3M -26M -4M -16M -1M -30M -35M
effectOfForexChangesOnCash -69 000 145 000 -116 000 -206 000 28 000 -279 000 387 000
netChangeInCash -43M 13M 26M -8M -13M -89M 30M
cashAtEndOfPeriod 55M 97M 84M 58M 66M 80M 169M
cashAtBeginningOfPeriod 97M 84M 58M 66M 80M 169M 139M
operatingCashFlow 7M 15M 10M 10M -8M 33M 21M
capitalExpenditure -4M -3M -5M -12M -2M 5M -5M
freeCashFlow 3M 12M 5M -2M -10M 38M 15M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2024 q1
2024-05-03 ET (fiscal 2024 q1)
2023 q4
2024-02-28 ET (fiscal 2023 q4)
2023 q3
2023-11-03 ET (fiscal 2023 q3)
2023 q2
2023-08-04 ET (fiscal 2023 q2)
2023 q1
2023-05-05 ET (fiscal 2023 q1)
2022 q4
2023-02-28 ET (fiscal 2022 q4)
2022 q3
2022-11-07 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-05-03 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-05-03 11:00 ET
Fulgent Reports First Quarter 2024 Financial Results
2024-04-11 20:05 ET
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
2024-02-28 12:00 ET
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-13 13:00 ET
Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024
2024-02-09 13:31 ET
Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing
2023-11-14 21:30 ET
Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference
2023-11-03 20:05 ET
Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting
2023-11-03 11:00 ET
Fulgent Reports Third Quarter 2023 Financial Results
2023-10-25 12:00 ET
Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting
2023-10-17 12:00 ET
Fulgent Genetics to Announce Third Quarter 2023 Financial Results on Friday November 3, 2023
2023-08-04 11:00 ET
Fulgent Reports Second Quarter 2023 Financial Results
2023-07-18 12:00 ET
Fulgent Genetics to Announce Second Quarter 2023 Financial Results on Friday, August 4, 2023
2023-06-05 12:30 ET
Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers
2023-05-18 20:05 ET
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting
2023-05-05 11:00 ET
Fulgent Reports First Quarter 2023 Financial Results
2023-04-20 20:05 ET
Fulgent Genetics to Announce First Quarter 2023 Financial Results on Friday May 5, 2023
2023-04-11 12:00 ET
Mission Bio Partners with Fulgent Genetics to Broaden Accessibility of Single-Cell Multi-Omics for Drug Development and Clinical Research
2023-02-28 21:05 ET
Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-28 21:03 ET
Fulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel
2023-02-23 21:05 ET
Fulgent to Participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference
2023-02-14 21:05 ET
Fulgent Genetics to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
2023-01-03 21:05 ET
Fulgent Expands Board of Directors with Addition of Reggie Groves
2022-12-27 14:30 ET
Barrack, Rodos & Bacine (BR&B) Is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) For Potential Investor Claims
2022-11-17 21:05 ET
Fulgent Genetics to Participate in Piper Sandler’s 34th Annual Healthcare Conference
2022-11-07 21:06 ET
Fulgent Genetics Acquires Fulgent Pharma, Creating a New Paradigm in Precision Medicine for The Company
2022-11-07 21:05 ET
Fulgent Genetics Reports Third Quarter 2022 Financial Results
2022-10-25 20:03 ET
Fulgent Genetics to Participate in Credit Suisse’s 31st Annual Healthcare Conference
2022-10-20 20:03 ET
Fulgent Genetics to Announce Third Quarter 2022 Financial Results on Monday November 7, 2022
2022-09-23 13:51 ET
INVESTOR ALERT: Edelson Lechtzin LLP is Investigating Securities Fraud Claims on Behalf of Fulgent Genetics, Inc. (NASDAQ: FLGT) Shareholders
2022-08-04 20:05 ET
Fulgent Genetics Reports Second Quarter 2022 Financial Results
2022-08-04 12:00 ET
Fulgent Genetics Announces Launch of PCR Based Test to Detect Monkeypox
2022-08-04 12:00 ET
Fulgent Genetics Welcomes Dr. Michael Nohaile and Dr. Leonard Post to Board of Directors
2022-07-19 12:00 ET
Fulgent Genetics to Announce Second Quarter 2022 Financial Results on Thursday, August 4, 2022
2022-07-05 12:00 ET
The American Medical Association Approves a New Category I CPT® Code for the HelioLiver™ Test
2022-05-03 20:05 ET
Fulgent Genetics Reports First Quarter 2022 Financial Results
2022-05-03 20:05 ET
Fulgent Genetics Announces Promotions and Leadership Updates
2022-05-03 12:00 ET
Fulgent Genetics Announces Opening of New State-of-the-Art Oncology Laboratory in El Monte, California
2022-04-27 16:05 ET
AVISTA CAPITAL PARTNERS COMPLETES SALE OF INFORM DIAGNOSTICS TO FULGENT GENETICS, INC.
2022-04-18 20:05 ET
Fulgent Genetics Agrees to Acquire Inform Diagnostics and Provides Preliminary First Quarter Revenue Results
2022-04-18 20:03 ET
Fulgent Genetics to Announce First Quarter 2022 Financial Results on Tuesday, May 3, 2022
2022-03-08 13:00 ET
Fulgent Genetics Announces $250 Million Share Repurchase Program
2022-03-08 13:00 ET
Representatives of Fulgent Genetics to Participate in Oppenheimer’s 32nd Annual Healthcare Conference
2022-03-07 13:00 ET
Helio Health Announces Publication of ENCORE Data in Hepatology Communications, Demonstrating Superior Performance of HelioLiver for Early Detection of Liver Cancer
2022-02-24 14:00 ET
EPIC SCIENCES AND FULGENT GENETICS COLLABORATE TO DELIVER DefineMBC™ RESULTS FOR METASTATIC BREAST CANCER PATIENTS
2022-02-23 21:05 ET
Fulgent Genetics Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-23 21:05 ET
Fulgent Genetics Announces Strategic Investment in Spatial Genomics
2022-02-14 13:00 ET
Fulgent Genetics to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday February 23, 2022
2021-12-06 13:00 ET
HelioLiver™, an Innovative Liquid Biopsy Test for the Early Detection of Liver Cancer, is Now Commercially Available
2021-12-01 21:40 ET
Fulgent Genetics Confirms Ability to Detect Omicron Variant with RT-PCR Tests for COVID-19
2021-11-09 21:05 ET
Fulgent Genetics Reports Third Quarter Financial Results
2021-11-09 13:00 ET
Representatives of Fulgent Genetics to Participate in Upcoming Virtual Conferences
2021-11-08 13:00 ET
Helio Health and Fulgent Genetics Announce Late-Breaking Positive Performance Data of HelioLiver™ for Early Liver Cancer Detection
2021-11-01 20:05 ET
Helio Health and Fulgent Genetics to Present New Data on HelioLiver in Late-Breaking Presentation at The Liver Meeting® 2021
2021-10-27 12:00 ET
Fulgent Genetics Launches At-Home Neutralizing Antibody Test for COVID-19
2021-10-25 12:00 ET
Fulgent Genetics to Announce Third Quarter 2021 Financial Results on Tuesday November 9, 2021
2021-09-23 20:05 ET
Fulgent Genetics to Partner with Houston Health Department and Houston-Area Public Schools on Back-to-School COVID-19 Testing Program
2021-08-09 20:05 ET
Fulgent Genetics Reports Second Quarter Financial Results
2021-08-09 20:02 ET
Fulgent Genetics and Helio Health Announce Strategic Partnership to Commercialize Early Cancer Detection Tests
2021-08-09 20:02 ET
Fulgent Genetics Announces Acquisition of CSI Laboratories
2021-07-26 12:00 ET
CORRECTING and REPLACING Fulgent Genetics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021
2021-05-10 12:00 ET
Fulgent Genetics Announces Incremental Strategic Investment in Chinese Joint Venture, FF Gene Biotech
2021-05-06 20:05 ET
Fulgent Genetics Reports Record First Quarter Financial Results
2021-05-06 12:00 ET
Fulgent Genetics Welcomes Dr. Lawrence Weiss as Chief Medical Officer
2021-04-16 12:00 ET
Fulgent Genetics to Announce First Quarter 2021 Financial Results on Thursday May 6, 2021
2021-03-15 20:05 ET
Fulgent Genetics Awarded Contract from CDC to Study Variants of COVID-19 Virus
2021-03-05 13:00 ET
Fulgent Genetics to Participate in the Oppenheimer 31st Annual Healthcare Conference
2021-03-04 21:05 ET
Fulgent Genetics Reports Record Fourth Quarter and Full Year 2020 Financial Results
2021-02-18 13:00 ET
Fulgent Genetics to Announce Fourth Quarter and Full Year 2020 Financial Results on Thursday March 4, 2021
2021-02-16 15:00 ET
BioIQ Partners with Fulgent Genetics to Bring COVID-19 Variant Detection to COVID-19 Testing Programs
2021-01-06 13:00 ET
Fulgent Genetics to Participate in the H.C. Wainwright BIOCONNECT 2021 Conference
2020-12-29 13:00 ET
Fulgent Genetics Extends Partnership with New York City Test and Trace for COVID-19 Testing, Awarded Contract for 2021 School Year
2020-12-17 21:02 ET
PRA Health Sciences collaborates with PWNHealth and Fulgent Genetics to provide at-home COVID-19 test capabilities
2020-11-24 13:00 ET
Fulgent Genetics to Participate in the Piper Sandler 32nd Annual Healthcare Conference
2020-11-23 13:00 ET
Fulgent Genetics Announces Increase to Full Year 2020 Guidance to $300 million
2020-11-18 13:30 ET
LANES, Fulgent Genetics and LA County Department of Health Services Collaborate to Fast-Track COVID-19 Test Results to Local Healthcare Providers
2020-11-10 21:05 ET
Fulgent Genetics to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference
2020-11-09 21:05 ET
Fulgent Genetics Reports Record Third Quarter 2020 Financial Results and Raises Full Year 2020 Revenue Guidance by $100 Million
2020-10-26 12:00 ET
Fulgent Genetics to Announce Third Quarter 2020 Financial Results on Monday November 9, 2020
2020-09-30 12:00 ET
Fulgent Genetics Announces Partnership with Ohio Department of Rehabilitation and Correction for COVID-19 Testing
2020-09-21 22:41 ET
Fulgent Genetics Set to Join S&P SmallCap 600
2020-09-15 12:00 ET
Fulgent Genetics to Provide COVID-19 Testing Solutions for the State of Utah
2020-09-09 12:00 ET
Fulgent Genetics, Miami-Dade County Partner on COVID-19 testing
2020-09-04 12:00 ET
Fulgent Genetics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference
2020-09-03 10:00 ET
Fulgent Genetics Adds Influenza A and Influenza B to all COVID-19 Tests
2020-09-02 20:05 ET
Fulgent Genetics, New York City Health and Hospitals Partner on Large-Scale Back-to-School COVID-19 Testing
2020-08-17 11:00 ET
Fulgent Genetics Announces Expansion into Houston, TX
2020-08-04 20:05 ET
Fulgent Genetics Reports Record Second Quarter 2020 Financial Results
2020-07-14 12:00 ET
Fulgent Genetics to Announce Second Quarter 2020 Financial Results on Tuesday August 4, 2020
2020-06-16 20:05 ET
Fulgent Genetics Announces FDA Authorization and Launch of At-Home Testing Service for COVID-19 
2020-05-18 10:00 ET
Fulgent Genetics Receives Emergency Use Authorization from the FDA for its RT-PCR Test for Detection of SARS-CoV-2, the Virus that Causes COVID-19
2020-05-04 20:05 ET
Fulgent Genetics Reports First Quarter 2020 Financial Results
2020-04-09 12:01 ET
Fulgent Genetics to Announce First Quarter 2020 Financial Results on Monday May 4, 2020
2020-04-09 12:00 ET
Fulgent Genetics Provides Update on Testing for COVID-19
2020-03-17 12:00 ET
Fulgent Genetics Announces Launch of Next Generation Sequencing (NGS) Test to Detect Coronavirus Disease (COVID-19)
2020-03-10 20:05 ET
Fulgent Genetics Reports Fourth Quarter and Full Year 2019 Financial Results
2020-03-10 12:00 ET
Fulgent Genetics Announces Promotion of Brandon Perthuis to Chief Commercial Officer
2020-02-20 13:00 ET
Fulgent Genetics to Announce Fourth Quarter and Full Year 2019 Financial Results on Tuesday March 10, 2020
2019-11-25 13:00 ET
Representatives of Fulgent Genetics to Participate in the Piper Jaffray 31st Annual Healthcare Conference
2019-11-14 04:15 ET
Fulgent Genetics Announces Pricing of Public Offering of Common Stock
2019-11-13 21:01 ET
Fulgent Genetics Announces Proposed Public Offering of Common Stock
2019-11-04 21:05 ET
Fulgent Genetics Reports Third Quarter 2019 Financial Results
2019-10-15 12:00 ET
Fulgent Genetics to Announce Third Quarter 2019 Financial Results on Monday November 4, 2019
2019-09-16 12:00 ET
Fulgent Genetics Launches Picture Genetics, a Consumer-Initiated Genetic Testing Offering
2019-04-18 12:00 ET
Fulgent Genetics to Announce First Quarter 2019 Financial Results on Tuesday May 7, 2019
2019-02-28 21:05 ET
Fulgent Genetics Reports Fourth Quarter and Full Year 2018 Financial Results
2019-02-20 13:00 ET
Fulgent Genetics to Announce Fourth Quarter and Full Year 2018 Financial Results on Thursday February 28, 2019

SEC forms

Show financial reports only

SEC form 10
2024-05-03 07:34 ET
Fulgent Genetics published news for 2024 q1
SEC form 8
2024-05-03 07:05 ET
Fulgent Genetics reported for 2024 q1
SEC form 8
2024-05-03 07:05 ET
Fulgent Genetics published news for 2024 q1
SEC form 8
2024-05-03 07:05 ET
Fulgent Genetics published news for 2024 q1
SEC form 10
2024-05-03 00:00 ET
Fulgent Genetics published news for 2024 q1
SEC form 10
2024-02-28 17:03 ET
Fulgent Genetics published news for 2023 q4
SEC form 8
2024-02-28 07:08 ET
Fulgent Genetics published news for 2023 q4
SEC form 8
2024-02-28 07:08 ET
Fulgent Genetics reported for 2023 q4
SEC form 8
2024-02-28 07:08 ET
Fulgent Genetics published news for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Fulgent Genetics published news for 2023 q4
SEC form 10
2023-11-03 07:31 ET
Fulgent Genetics published news for 2023 q3
SEC form 8
2023-11-03 07:09 ET
Fulgent Genetics reported for 2023 q3
SEC form 10
2023-11-03 00:00 ET
Fulgent Genetics published news for 2023 q3
SEC form 10
2023-08-04 07:14 ET
Fulgent Genetics reported for 2023 q2
SEC form 6
2023-08-04 07:07 ET
Fulgent Genetics published news for 2023 q2
SEC form 10
2023-08-04 00:00 ET
Fulgent Genetics published news for 2023 q2
SEC form 8
2023-08-04 00:00 ET
Fulgent Genetics published news for 2023 q2
SEC form 8
2023-05-05 00:00 ET
Fulgent Genetics published news for 2023 q1
SEC form 10
2023-05-05 00:00 ET
Fulgent Genetics published news for 2023 q1
SEC form 10
2023-02-28 16:49 ET
Fulgent Genetics reported for 2022 q4
SEC form 6
2023-02-28 16:24 ET
Fulgent Genetics published news for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Fulgent Genetics reported for 2022 q4
SEC form 8
2023-02-28 00:00 ET
Fulgent Genetics reported for 2022 q4
SEC form 6
2023-01-12 16:10 ET
Fulgent Genetics published news for 2022 q4
SEC form 6
2023-01-04 16:34 ET
Fulgent Genetics published news for 2022 q4
SEC form 6
2023-01-03 16:11 ET
Fulgent Genetics published news for 2022 q4
SEC form 6
2022-11-23 16:09 ET
Fulgent Genetics published news for 2022 q3
SEC form 10
2022-11-07 16:36 ET
Fulgent Genetics reported for 2022 q3
SEC form 6
2022-11-07 16:11 ET
Fulgent Genetics published news for 2022 q3
SEC form 10
2022-11-07 00:00 ET
Fulgent Genetics reported for 2022 q3
SEC form 8
2022-11-07 00:00 ET
Fulgent Genetics reported for 2022 q3
SEC form 6
2022-11-04 16:05 ET
Fulgent Genetics published news for 2022 q3
SEC form 6
2022-09-29 16:15 ET
Fulgent Genetics published news for 2022 q2
SEC form 6
2022-08-10 18:06 ET
Fulgent Genetics published news for 2022 q2
SEC form 10
2022-08-04 17:03 ET
Fulgent Genetics reported for 2022 q2
SEC form 6
2022-08-04 16:39 ET
Fulgent Genetics published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Fulgent Genetics reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Fulgent Genetics reported for 2022 q2
SEC form 6
2022-08-03 17:34 ET
Fulgent Genetics published news for 2022 q2
SEC form 6
2022-06-30 16:07 ET
Fulgent Genetics published news for 2022 q1
SEC form 6
2022-05-19 16:19 ET
Fulgent Genetics published news for 2022 q1
SEC form 10
2022-05-05 16:51 ET
Fulgent Genetics reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Fulgent Genetics reported for 2022 q1
SEC form 6
2022-05-03 16:10 ET
Fulgent Genetics published news for 2022 q1
SEC form 8
2022-05-03 00:00 ET
Fulgent Genetics reported for 2022 q1
SEC form 6
2022-04-26 16:43 ET
Fulgent Genetics published news for 2022 q1
SEC form 6
2022-04-18 16:13 ET
Fulgent Genetics published news for 2022 q1
SEC form 6
2022-03-29 16:33 ET
Fulgent Genetics published news for 2021 q4
SEC form 6
2022-03-29 16:23 ET
Fulgent Genetics published news for 2021 q4
SEC form 10
2022-02-28 08:13 ET
Fulgent Genetics published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Fulgent Genetics published news for 2021 q4
SEC form 6
2022-02-23 16:10 ET
Fulgent Genetics published news for 2021 q4
SEC form 8
2022-02-23 00:00 ET
Fulgent Genetics published news for 2021 q4
SEC form 10
2021-11-09 17:13 ET
Fulgent Genetics published news for 2021 q3
SEC form 6
2021-11-09 16:11 ET
Fulgent Genetics published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Fulgent Genetics published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Fulgent Genetics published news for 2021 q3
SEC form 10
2021-08-10 00:00 ET
Fulgent Genetics published news for 2021 q2
SEC form 10
2021-08-09 21:32 ET
Fulgent Genetics published news for 2021 q2
SEC form 6
2021-08-09 16:25 ET
Fulgent Genetics published news for 2021 q2
SEC form 6
2021-05-20 17:12 ET
Fulgent Genetics published news for 2021 q1
SEC form 10
2021-05-07 16:07 ET
Fulgent Genetics published news for 2021 q1
SEC form 10
2021-05-07 00:00 ET
Fulgent Genetics published news for 2021 q1
SEC form 6
2021-05-06 16:20 ET
Fulgent Genetics published news for 2021 q1
SEC form 6
2021-04-01 16:16 ET
Fulgent Genetics published news for 2021 q1
SEC form 10
2021-03-08 17:17 ET
Fulgent Genetics published news for 2020 q4
SEC form 6
2021-03-04 16:07 ET
Fulgent Genetics published news for 2020 q4
SEC form 6
2021-02-05 16:40 ET
Fulgent Genetics published news for 2020 q4
SEC form 6
2020-12-22 17:08 ET
Fulgent Genetics published news for 2020 q3
SEC form 6
2020-11-23 08:12 ET
Fulgent Genetics published news for 2020 q3
SEC form 6
2020-11-20 17:03 ET
Fulgent Genetics published news for 2020 q3
SEC form 10
2020-11-09 16:24 ET
Fulgent Genetics published news for 2020 q3
SEC form 6
2020-11-09 16:11 ET
Fulgent Genetics published news for 2020 q3
SEC form 6
2020-10-21 16:17 ET
Fulgent Genetics published news for 2020 q3